May/June 2021
IP Litigator
The law on whether medical diagnostic methods are patent-eligible can be challenging. Inventors who have heard of cases like Myriad Genetics may end up believing that methods of diagnosing disease are per-se ineligible for patent protection under 35 U.S.C. § 101. Judge Moore of the Federal Circuit has remarked that “[s]ince Mayo, we have held every single diagnostic claim in every case before us ineligible.” Yet the Federal Circuit has hinted that inventions in the medical diagnostic space may be eligible or protection when the claims are directed to applications of laws of nature rather than the laws of nature themselves. Recent caselaw highlights the line that divides ineligible and eligible subject matter.
Read "A Retrospective on Myriad Genetics: What Makes Medical Diagnostics Patent-Eligible 8 Years Later?"
Reprinted with permission from the IP Litigator, published by Wolters Kluwer. This article is for informational purposes, is not intended to constitute legal advice, and may be considered advertising under applicable state laws. This article is only the opinion of the authors and is not attributable to Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, or the firm’s clients.
Conference
2024 Hispanic National Bar Association Annual Convention
September 4-6, 2024
National Harbor
Webinar
June 13, 2024
Webinar
Conference
4th Spring Pharmaceutical Synchrotron X-Ray Powder Diffraction Workshop
June 10-11, 2024
Basel
June 10-12, 2024
San Francisco
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.